Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2003 Dec;58(12):1027–1030. doi: 10.1136/thorax.58.12.1027

Correlation between annual change in health status and computer tomography derived lung density in subjects with α1-antitrypsin deficiency

J Stolk 1, W Ng 1, M Bakker 1, J Reiber 1, K Rabe 1, H Putter 1, B Stoel 1
PMCID: PMC1746549  PMID: 14645966

Abstract

Methods: Twenty two patients of mean (SD) age 40.7 (9.2) years with ZZ type α1-antitrypsin deficiency were investigated at baseline and 30 months later by FEV1 and KCO, St George Respiratory Questionnaire (SGRQ), and by a spiral CT scan of the chest. CT data of chest images were analysed using software designed for automated lung contour detection and lung density measurements. The density data were corrected for changes in inspiration levels.

Results: Changes in lung density, expressed as 15th percentile point or relative area below –950 HU, correlated well with changes in health status (SGRQ total score): R = –0.56, p = 0.007 or R = 0.6, p = 0.003. Neither changes in health status nor changes in lung density correlated significantly with changes in FEV1 or changes in KCO.

Conclusions: The SGRQ total score (which is a global measure in COPD) and lung density (a specific measure of emphysema) are sensitive to deterioration in patients with α1-antitrypsin deficiency. This finding may facilitate future studies with new drugs specific for emphysema, a frequently occurring component of COPD.

Full Text

The Full Text of this article is available as a PDF (232.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black L. F., Kueppers F. alpha1-Antitrypsin deficiency in nonsmokers. Am Rev Respir Dis. 1978 Mar;117(3):421–428. doi: 10.1164/arrd.1978.117.3.421. [DOI] [PubMed] [Google Scholar]
  2. Burge P. S., Calverley P. M., Jones P. W., Spencer S., Anderson J. A., Maslen T. K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May 13;320(7245):1297–1303. doi: 10.1136/bmj.320.7245.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dirksen A., Dijkman J. H., Madsen F., Stoel B., Hutchison D. C., Ulrik C. S., Skovgaard L. T., Kok-Jensen A., Rudolphus A., Seersholm N. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1468–1472. doi: 10.1164/ajrccm.160.5.9901055. [DOI] [PubMed] [Google Scholar]
  4. Dowson L. J., Guest P. J., Stockley R. A. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1805–1809. doi: 10.1164/ajrccm.164.10.2106036. [DOI] [PubMed] [Google Scholar]
  5. ERIKSSON S. PULMONARY EMPHYSEMA AND ALPHA1-ANTITRYPSIN DEFICIENCY. Acta Med Scand. 1964 Feb;175:197–205. doi: 10.1111/j.0954-6820.1964.tb00567.x. [DOI] [PubMed] [Google Scholar]
  6. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977 Jun 25;1(6077):1645–1648. doi: 10.1136/bmj.1.6077.1645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gevenois P. A., De Vuyst P., de Maertelaer V., Zanen J., Jacobovitz D., Cosio M. G., Yernault J. C. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med. 1996 Jul;154(1):187–192. doi: 10.1164/ajrccm.154.1.8680679. [DOI] [PubMed] [Google Scholar]
  8. Gould G. A., MacNee W., McLean A., Warren P. M., Redpath A., Best J. J., Lamb D., Flenley D. C. CT measurements of lung density in life can quantitate distal airspace enlargement--an essential defining feature of human emphysema. Am Rev Respir Dis. 1988 Feb;137(2):380–392. doi: 10.1164/ajrccm/137.2.380. [DOI] [PubMed] [Google Scholar]
  9. Jones P. W., Bosh T. K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997 Apr;155(4):1283–1289. doi: 10.1164/ajrccm.155.4.9105068. [DOI] [PubMed] [Google Scholar]
  10. Jones P. W. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002 Mar;19(3):398–404. doi: 10.1183/09031936.02.00063702. [DOI] [PubMed] [Google Scholar]
  11. Jones P. W., Quirk F. H., Baveystock C. M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321–1327. doi: 10.1164/ajrccm/145.6.1321. [DOI] [PubMed] [Google Scholar]
  12. Piitulainen E., Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J. 1999 Feb;13(2):247–251. doi: 10.1183/09031936.99.13224799. [DOI] [PubMed] [Google Scholar]
  13. Spencer S., Calverley P. M., Sherwood Burge P., Jones P. W., ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Jan;163(1):122–128. doi: 10.1164/ajrccm.163.1.2005009. [DOI] [PubMed] [Google Scholar]
  14. Stockley R. A. Alpha-1-antitrypsin deficiency: what next? Thorax. 2000 Jul;55(7):614–618. doi: 10.1136/thorax.55.7.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Stoel B. C., Vrooman H. A., Stolk J., Reiber J. H. Sources of error in lung densitometry with CT. Invest Radiol. 1999 Apr;34(4):303–309. doi: 10.1097/00004424-199904000-00008. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Publisher Correction]
thorax_58_12_1027__index.html (1.1KB, html)

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES